

Paradigm appoints Business Development Consultant

Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”), a late-stage drug development company focused on delivering new therapies to address unmet medical needs, is pleased to announce the appointment of Scott Williams (via company Fiftyone Capital Pty Ltd) as a Business Development Consultant. Mr. Williams will work with Paradigm to support the Company's efforts in executing one or more regional pharmaceutical deals for injectable Pentosan Polysulfate Sodium (iPPS), which are intended to provide non-dilutionary funding for its clinical programs.

"We are excited to engage Scott Williams as a Business Development Consultant," said Paul Rennie, CEO of Paradigm Biopharmaceuticals. "His experience in business development and deal execution will assist in pursuing commercial transactions that we expect will substantially increase shareholder value."

Paradigm looks forward to a fruitful collaboration with Scott Williams, as the Company continues to work towards strategic partnerships and licensing agreements to bring iPPS to patients in need.

Consultancy Agreement

As a part of the terms of agreement for consultancy, Fiftyone Capital has agreed to be aligned by way of shareholder success and, as such, has a modest monthly retainer and will be mostly remunerated with the issue of 7.5m out of the money unlisted options on the following terms:

- (a) 2.5m options – with an exercise price of \$0.65 – 2-year expiry from issue date (issued immediately).
- (b) 2.5m options – with an exercise price of \$1.00 – 2-year expiry from issue date (issued if and upon the Company entering into at least one binding commercial agreement disclosable under ASX Listing Rule 3.1, before 31 July 2025).
- (c) 2.5m options – with an exercise price of \$1.35 – 2-year expiry from issue date (issued if and upon the Company entering into at least one binding commercial agreement disclosable under ASX Listing Rule 3.1, before 31 July 2025).

-Ends-

About Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients' health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm's current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (**iPPS**) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of iPPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).

Forward Looking Statements

This Company announcement contains forward-looking statements, including statements regarding anticipated commencement dates or completions dates of preclinical or clinical trials, regulatory developments and regulatory approval. These forward-looking statements are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this presentation. Readers are cautioned not to put undue reliance on forward-looking statements.

To learn more please visit: <https://paradigmbiopharma.com>

Approved for release by the Paradigm Board of Directors.

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com